糖原合成酶激酶-3:糖尿病的潜在目标
Divya M Teli1, Anuradha K Gajjar1
1Department of Pharmaceutical Chemistry and Quality Assurance, L. M. College of Pharmacy, Ahmedabad, Gujarat 380009, India.
Bioorganic & medicinal chemistry
|August 3, 2023
概括
葡萄糖合成酶激酶-3 (GSK-3) 抑制剂通过向葡萄糖代谢来治疗II型糖尿病有望. 研究重点是结构分析和分子建模,以开发有效的抗糖尿病治疗方法.
科学领域:
- 生物化学 生物化学
- 药理学 药理学 是一个学科.
- 分子生物学分子生物学
背景情况:
- 由于β细胞功能障碍而导致葡萄糖水平升高是II型糖尿病的标志.
- 糖原合成酶激酶-3 (GSK-3) 在调节糖原代谢中起着至关重要的作用.
- 目前正在研究GSK-3抑制剂的潜在抗糖尿病作用.
研究的目的:
- 审查GSK-3的结构分析和分子建模.
- 探索GSK-3信号通路作为糖尿病的治疗点.
- 讨论开发用于II型糖尿病的新型GSK-3抑制剂的进展.
主要方法:
- 对GSK-3的结构数据的检查.
- 分子建模研究的分析.
- 关于GSK-3法规的细胞生物学研究的审查.
主要成果:
- 阐明GSK-3的监管机制.
- 识别与抑制器设计相关的结构特征.
- 对GSK-3抑制剂的分子修饰策略的概述.
结论:
- GSK-3是第二类糖尿病的可行的治疗点.
- 结构和分子建模的洞察力指导GSK-3抑制剂的开发.
- 对分子修饰的持续研究可以导致新的抗糖尿病药物.
相关概念视频
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Hypoglycemia and Glucagon
301
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
301
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K


